Search by Drug Name or NDC
NDC 50268-0086-12 Atovaquone 750 mg/5mL Details
Atovaquone 750 mg/5mL
Atovaquone is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AvPAK. The primary component is ATOVAQUONE.
MedlinePlus Drug Summary
Atovaquone is used to treat Pneumocystis jiroveci [Pneumocystis carinii] pneumonia (PCP; type of pneumonia most likely to affect people with human immunodeficiency virus [HIV]) in teenagers and adults. Atovaquone is also used to prevent PCP in teenagers and adults who cannot take another medication used for prevention. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia.
Related Packages: 50268-0086-12Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Atovaquone
Product Information
NDC | 50268-0086 |
---|---|
Product ID | 50268-086_d5cbb80c-c326-ac08-e053-2995a90a264d |
Associated GPIs | 16400020001820 |
GCN Sequence Number | 023399 |
GCN Sequence Number Description | atovaquone ORAL SUSP 750 MG/5ML ORAL |
HIC3 | W4K |
HIC3 Description | ANTIPROTOZOAL DRUGS,MISCELLANEOUS |
GCN | 34490 |
HICL Sequence Number | 006619 |
HICL Sequence Number Description | ATOVAQUONE |
Brand/Generic | Generic |
Proprietary Name | Atovaquone |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Atovaquone |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | SUSPENSION |
Route | ORAL |
Active Ingredient Strength | 750 |
Active Ingredient Units | mg/5mL |
Substance Name | ATOVAQUONE |
Labeler Name | AvPAK |
Pharmaceutical Class | Antimalarial [EPC], Antiprotozoal [EPC] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA210692 |
Listing Certified Through | 2025-12-31 |
Package
NDC 50268-0086-12 (50268008612)
NDC Package Code | 50268-086-12 |
---|---|
Billing NDC | 50268008612 |
Package | 20 CUP, UNIT-DOSE in 1 BOX (50268-086-12) / 5 mL in 1 CUP, UNIT-DOSE (50268-086-11) |
Marketing Start Date | 2020-05-07 |
NDC Exclude Flag | N |
Pricing Information | N/A |